EUVIMEDEUVIMED entdecken
Crossref

Formulation and In Vitro Evaluation of a Bilayer Tablet of Sustained-Release Metoprolol Succinate and Immediate-Release Amlodipine Besylate for Daily Hypertension Management

Sunku Sravani, Bala Sai Soujith Nidamanuri, Hindustan Abdul Ahad, S B Thirumalesh Naik

International Journal of Drug Delivery Technology · 02.06.2026 · 16 (44s)

DOI: 10.25258/ijddt.16.44s.146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 02.06.2026. Verfasst von Sunku Sravani und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension affects 1.3 billion adults globally, with nearly 70% needing two antihypertensive agents for target blood pressure; however, multi-pill regimens hinder adherence. This study developed a once-daily single-pill bilayer tablet with immediate-release (IR) amlodipine besylate and sustained-release (SR) metoprolol succinate. Nine bilayer formulations (F1–F9) were prepared by direct compression, using sodium starch glycolate in the IR layer and a hydrophilic SR matrix of HPMC K100M and xanthan gum, with starch 1500 and dibasic calcium phosphate as diluents, polyvinylpyrrolidone as a binder, Aerosil as a glidant, and magnesium stearate as a lubricant. The tablets were film-coated with an HPMC-based clear coat plasticized with PEG 6000 and talc. Drug quantification was done by UV spectrophotometry (metoprolol: 224 nm, 275 nm; amlodipine: 360 nm), and compatibility was assessed by FTIR and DSC, including analysis of drug–excipient mixtures stored at 40°C and 75–80% RH for 28 days. All powder blends exhibited acceptable flow/compressibility, and the tablets met the pharmacopoeial limits for hardness, friability, weight variation, and content uniformity. Dissolution testing showed rapid amlodipine release (>96% within 30 min), while metoprolol release depended on the polymer load: low-polymer batches showed burst release, whereas higher loads produced controlled profiles. F6 was optimal, achieving 99.92% metoprolol release over 12 h with near-zero-order behavior (R² = 0.9785) governed by anomalous transport (Korsmeyer–Peppas n = 0.710; R² = 0.9927). The optimized bilayer tablet integrates complementary antihypertensives into a once-daily dosage form, potentially reducing the pill burden and supporting adherence; further in vivo bioequivalence, ICH stability, scale-up robustness, and QbD-driven optimization are needed for clinical translation.

Zitieren

APA

Sravani, S., Nidamanuri, B. S. S., Ahad, H. A., & Naik, S. B. T. (2026). Formulation and In Vitro Evaluation of a Bilayer Tablet of Sustained-Release Metoprolol Succinate and Immediate-Release Amlodipine Besylate for Daily Hypertension Management. International Journal of Drug Delivery Technology, 16(44s). https://doi.org/10.25258/ijddt.16.44s.146

Vancouver

Sravani S, Nidamanuri BSS, Ahad HA, Naik SBT. Formulation and In Vitro Evaluation of a Bilayer Tablet of Sustained-Release Metoprolol Succinate and Immediate-Release Amlodipine Besylate for Daily Hypertension Management. International Journal of Drug Delivery Technology. 2026;16(44s). doi:10.25258/ijddt.16.44s.146

BibTeX
@article{Sravani2026,
  author = {Sravani, Sunku and Nidamanuri, Bala Sai Soujith and Ahad, Hindustan Abdul and Naik, S B Thirumalesh},
  title = {Formulation and In Vitro Evaluation of a Bilayer Tablet of Sustained-Release Metoprolol Succinate and Immediate-Release Amlodipine Besylate for Daily Hypertension Management},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {44s},
  doi = {10.25258/ijddt.16.44s.146}
}
Kostenlos starten →